Compare BCHT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCHT | RLYB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 15 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.0M | 44.6M |
| IPO Year | 2026 | 2021 |
| Metric | BCHT | RLYB |
|---|---|---|
| Price | $1.62 | $8.22 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 96.2K | 76.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $858,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $61.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.61 | $0.25 |
| 52 Week High | $2.45 | $11.49 |
| Indicator | BCHT | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 30.60 | 49.52 |
| Support Level | N/A | $7.90 |
| Resistance Level | $2.33 | $9.25 |
| Average True Range (ATR) | 0.18 | 0.44 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 7.06 | 21.56 |
Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.